Optometrists should advise their patients that although these medications are conclusively linked to an increased risk of NAION, the overall risk is still extremely low: only about 2.30 per 100,000 people are diagnosed with NAION each year
In another case report by Fujino et al., a 31-year-old female patient on semaglutide for T2DM underwent EGD in preparation for bariatric surgery
The addition of GIP receptor activity may actually reduce GLP-1 related gastrointestinal discomfort rather than adding to it
At 8mg specifically, 100% of participants lost at least 5% of their body weight, 91% lost at least 10%, and 75% lost at least 15%
Blood tests allow providers to measure growth hormone activity and ensure treatment is working effectively without pushing hormone levels too high
This often involves documenting the patients health conditions, failed attempts at weight loss, and the potential benefits of the surgery